HiFiBiO SAS to Report Results from the First Fully Integrated, Single-Cell Antibody Discovery Platform at IBC Antibody and Engineering Therapeutics 2015 Conference

In Uncategorized by Adam Woolfe

Screening entire immune repertoires generates diverse panels of therapeutic antibody leads

CAMBRIDGE, Mass. & PARIS–(BUSINESS WIRE)–HiFiBiO SAS today announced that the latest results from their CelliGOTM platform will be presented by Chief Scientific Officer, Dr. Allan Jensen, Dec. 7-10 San Diego, California. The presentation, will be on Tuesday, Dec. 8 at 13:45 (PST) and will feature important case studies and new data.

IBC Antibody Engineering and Therapeutics LogoPresentation Title: A Fully Integrated Antibody Discovery Engine for Accelerated Drug Candidate Selection Against Complex Targets
HiFiBiO has achieved the identification of highly diverse panels of specific antibodies to a range of recombinant protein and cell-surface presented targets, and some of these case stories will be presented as examples. The entire immune repertoire of an immunized mouse was rapidly screened on a single-cell basis using microfluidic droplet technology by interrogating B-cells directly and then rapidly preserving and confirming the binding specificity enabling an unprecedented throughput in screening capability and fidelity. Direct screening of patient memory B-cells using droplet microfluidics has also been accomplished.

About HiFiBiO
HiFiBiO’s platform employs paired bar coding, next generation sequencing and rapid DNA synthesis coupled to high throughput cloning and expression enabling single cell-based screening of entire antibody-secreting B cell populations . Identification of diverse high quality leads is expected to lower the risk of developing optimized antibody drug candidates. The company has entered into multiple antibody discovery collaborations with leading pharmaceutical companies. Learn more at www.hifibio.com.


Colin J.H. Brenan, Ph.D., +1 781-248-9318
Chief Commercial Officer